SCL Science

SCL Science Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of SCL Science (246960.KQ) as of Nov 18, 2026 is 26.16 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 159.75 % — a change of -83.62% (lower).

Cash Conversion

26.16 %

YoY

-83.62%

Last updated:

Cash Conversion Rate (OCF/Net Income) of SCL Science is 2025 26.16 % . Cash Conversion Rate (OCF/Net Income) of SCL Science was 2024 159.75 % . It decreases by -83.62% lower compared to the previous year.

The SCL Science Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
84.66 KRW
Jan 1, 2019
81.82 KRW
Jan 1, 2020
94.23 KRW
Jan 1, 2021
79.21 KRW
Jan 1, 2022
68.73 KRW
Jan 1, 2023
56.09 KRW
Jan 1, 2024
159.75 KRW
Jan 1, 2025
26.16 KRW
The SCL Science Cash Conversion history
YEARCash ConversionYoY
26.16 %-83.62%
159.75 %+184.79%
56.09 %-18.39%
68.73 %-13.22%
79.21 %-15.94%
94.23 %+15.16%
81.82 %-3.35%
84.66 %+12.84%
75.02 %-48.02%
144.31 %+505.03%
23.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Cash Conversion Rate (OCF/Net Income) of SCL Science is 26.16 % in 2025.

Cash Conversion Rate (OCF/Net Income) of SCL Science changed from 159.75 % to 26.16 %, representing a -83.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) SCL Science since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s SCL Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SCL Science

All Key Metrics — SCL Science